SPDL1 and renal pelvis/ureter urothelial carcinoma: Specifically, among cancer patients treated with chemotherapy, higher baseline sPD-L1 levels correlated with shorter OS in those patients with NSCLC [46], gastric cancer [217, 218], pancreatic cancer [219, 220], urothelial cancer [81], and upper tract urothelial carcinoma [89].